Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eton Pharmaceuticals reports robust Q4 earnings, eyes accelerated growth

Eton Pharmaceuticals reported strong financial performance in Q4 2022, with a focus on accelerating growth, expanding product portfolio, and doubling sales and royalty revenue in 2023. The strategic transition to an in-house sales force for key products reflects proactive sales strategy control and market expansion efforts. While facing challenges in managing increased R&D expenses, Eton is well-positioned to capitalize on growth opportunities and achieve its long-term goal of commercializing rare disease products.

Eton Pharmaceuticals Reports Record Sales in Q1 2023, Eyes Growth

Eton Pharmaceuticals delivered impressive Q1 results with record sales and revenue growth, driven by successful product launches and strategic marketing initiatives. While facing challenges in managing expenses and legal matters, the company remains optimistic about its growth prospects and product development plans.

Eton Pharmaceuticals excels in Q2, eyes rare disease expansion

Eton Pharmaceuticals demonstrated strong financial performance and strategic growth initiatives in Q2 2023.
While facing regulatory challenges and timeline risks, the company's focus on rare diseases and acquisitions positions it for future growth.
With a solid cash position, successful product launches, and revenue projections, Eton is poised for continued success and value creation.
Navigating challenges and capitalizing on opportunities will be crucial for Eton to sustain its growth trajectory and maximize shareholder value.

Eton Pharmaceuticals excels in Q3, eyes rare disease market growth

Eton Pharmaceuticals demonstrated strong financial performance in Q3 2023, driven by revenue growth and operational efficiency.
While facing challenges in expense management and short-term profitability, the company remains focused on expanding its product portfolio and market presence.
With a solid cash position, strategic acquisitions, and a clear growth strategy, Eton is poised for continued success and revenue expansion in the coming quarters.

Eton Pharmaceuticals excels in Q4, eyes positive net income in 2024

Eton Pharmaceuticals delivered strong financial performance in Q4 2023, with revenue growth, positive cash flow, and a path to positive GAAP net income in 2024. The company's well-capitalized position, promising pipeline, and strategic growth initiatives position it for continued success. However, managing increasing operating expenses and ensuring the accretive nature of future acquisitions are key challenges.

Eton Pharmaceuticals reports robust Q1 revenue growth and strategic expansions

Eton Pharmaceuticals' Q1 performance reflects consistent revenue growth and strategic advancements.
While facing competition and M&A caution, the company is poised for growth with new products.
Opportunities lie in upcoming NDA approvals, product developments, and maintaining financial discipline.
Overall, Eton's prudent financial management and growth strategies position it for future success.

Eton Pharmaceuticals reports record Q3 earnings, eyes transformative acquisition

Eton Pharmaceuticals delivered strong financial performance in Q3 2024, with robust revenue growth, positive net income, and a strategic acquisition on the horizon. While facing challenges in sales force realignment and increased expenses, the company is poised to capitalize on opportunities with Increlex and ET-400.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late June is discussed.

Volume Breakout Report Update: Buy Eton Pharmaceuticals

Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.

ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection

Aprea Therapeutics

Bionano Genomics

Fresh Tracks Therapeutics Inc

4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch In January 2023

-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) response for dehydrated alcohol injection for the proposed indication of methanol poisoning. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2023.

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

Shares have lost 25% of their value in 2023. Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity and providing a low-dose option of hydrocortisone treatment.

Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants David Krempa - Senior Vice President, Business Development & Investor Relations Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Eton Pharmaceuticals' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode.

Eton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 20% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates

DEER PARK, Ill., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2022.

Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results

DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the LD Micro Main Event XV Conference as follows:

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution.

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants David Krempa - Senior Vice President of Business Development & Investor Relations Sean Brynjelsen - President & Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good afternoon and welcome to the Eton Pharmaceuticals Second Quarter '22 Financial Results Conference Call.

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2022 Results - Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022.

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy?

Eton Pharmaceuticals (ETON) stock is on the rise Monday as investors react to news of approval from the FDA for Zonisade. The post Eton Pharmaceuticals (ETON) Stock Is Up 10% on FDA Approval appeared first on InvestorPlace.

Eton Pharmaceuticals (ETON) Stock Is Up 10% on FDA Approval

Eton Pharmaceuticals Inc (NASDAQ: ETON) shares are trading higher Monday after the company announced FDA approval of ZONISADE. ZONISADE was included in Eton's multi-product partnership with Azurity Pharmaceuticals, which was announced in February 2021.

Why Eton Pharmaceuticals Stock Is Moving Higher

Shares of Eton Pharmaceuticals Inc. ETON, +3.33% jumped 16.5% in premarket trading on Monday after the company said the Food and Drug Administration approved Zonisade, a seizure treatment for adults and teens older than 16 years old with epilepsy. Per a deal last year with the privately held Azurity Pharmaceuticals Inc., Eton will receive $5 million for the launch of the drug, royalties on net sales, and up to $15 million in commercial milestones for Zonisade and two other therapies included in the deal.

Eton's stock gains 16% after announcing FDA approval of epilepsy drug

DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONISADE™ (zonisamide oral suspension).

Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospital products allows us to focus our resources on our core.

Eton Pharma Shares Tick Higher After Offloading Hospital Products

DEER PARK, Ill., June 24, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, “Dr Reddy's”) (NYSE: RDY) for total payments of up to $50 million.

Eton Pharmaceuticals Announces Sale of Hospital Products

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -162.50% and 69.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Mitchell Kapoor – H. C. Wainwright Justin Walsh – B.

Eton Pharmaceuticals, Inc.'s (ETON) CEO Sean Brynjelsen on Q1 2021 Results - Earnings Call Transcript

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022.

News for Eton Pharmaceuticals Inc Stock (ETON)